A recent study from the Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “Loss of Fbw7 Reprograms Adult Pancreatic Ductal Cells into α, δ, and β Cells.“ This study was published in the August 7 2014 Cell Stem Cell by Prof Axel Behrens, Rocio Sancho, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based Regenerative therapy for T2D: MiRNA-223 promotes reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3. This study suggests that MiRNA-223, by increasing the expression of Ngn3 in adult pancreatic ductal cells, it may reprogram adult pancreatic ductal cells into β cells. Thereby, it may induce the expression of Ngn3, increase insulin secretion and inhibit insulin resistance. Together, this study suggests that pharmacological formulations encompassing“MiRNA-223 activators” may be used to regenerate β cells in T2D patients.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based Regenerative therapy for T2D: MiRNA-223 promotes reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3, 14/August/2014, 19.41, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
